The MAGE-A3 immunotherapeutic is composed of MAGE-A3 protein with the immunostimulant AS15, a combination of 3-O-desacyl-4'-monophosphoryl lipid A (MPL, 50 µg, produced by GSK), Quillaja saponaria Molina, fraction 21 (QS-21, 50 µg, licensed by GSK from Antigenics Inc., a wholly owned subsidiary of Agenus Inc., a Delaware, USA corporation) and CpG 7909 synthetic oligodeoxynucleotides containing unmethylated CpG motifs (420 µg), in a liposomal formulation. The recombinant MAGE-A3 protein was co-lyophilized with the immunostimulatory nucleotide CpG 7909 (from the AS15 adjuvant system) and reconstituted with 0.5 ml of liquid adjuvant in phosphate-buffered saline.
Of note, at the time of the study, the RECIST criteria were the only available response evaluation criteria in solid tumors; recently however, new immune-related response criteria have been proposed for evaluation of atypical response patterns. [2] 3.1. Objective tumor response criteria
The RECIST criteria
Objective tumor response was measured according to the RECIST criteria. [1] Response criteria were based on a set of measurable lesions identified at baseline as target lesions, and followed until disease progression. All measurable lesions (up to a maximum of five lesions per organ and 10 lesions in total), representative of all involved organs, were identified as target lesions and were recorded and measured at baseline. Target lesions were selected on the basis of their size (those with the LD) and their suitability for accurate repetitive measurements (either by imaging techniques or clinically). A sum of the LD for all target lesions was calculated and reported as the baseline sum LD. The baseline sum LD was used as reference to characterize the objective tumor response. All other lesions (or sites of disease) were identified as non-target lesions and were also recorded and measured at baseline. Measurements were not required but the presence or absence of each was noted throughout follow-up. Mixed response (MR) according to the RECIST criteria was defined as:
at least 30% decrease in the LD occurring in at least one target lesion recorded and measured at baseline. Such response occurring in otherwise SD or PD status of the LD of target lesions and without the appearance of one or more new lesions was classified as SD with target lesion regression or PD with target lesion regression, respectively; or appearance of one or more new lesions occurring in otherwise SD or PR status of the LD of target lesions, classified as SD with new lesion or PR with new lesion, respectively.
Tumor response for cutaneous/subcutaneous/lymph node disease with target lesions of <20 mm
Similar to standard RECIST criteria, response criteria for patients with cutaneous, subcutaneous or lymph node disease with target lesions of <20 mm were based on a set of measurable lesions identified at baseline as target lesions, and followed until disease progression.
All measurable cutaneous/subcutaneous/lymph node lesions and measurable cutaneous confluent lesions up to a maximum of five lesions per site (skin, subcutaneous or lymph node) were identified as target lesions and were recorded and measured at baseline, as follows:
CR: disappearance of all target lesions PR/SD: neither sufficient shrinkage to qualify for CR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started.
PD: according to investigator, clear increase of diameters of target lesions taking as references the smallest diameters recorded since the treatment started or the appearance of one or more new target lesions or both of these.
MR for patients with cutaneous and/or sub-cutaneous and/or lymph node disease that could not be evaluated according to RECIST criteria was defined as: a clear decrease of diameters occurring in at least one target lesion recorded and measured at baseline. Such response occurring in otherwise SD or PD status of the LD of (baseline) target lesions and without the appearance of one or more new lesions was classified as "SD with target lesion regression" or "PD with target lesion regression", respectively; or appearance of one or more new lesions occurring in otherwise SD or PR status of the LD of target lesions. Such response was to be classified as "SD with new lesion" or "PR with new lesion", respectively.
Response criteria for patients with both target lesion(s) ≥ 20 mm and target lesion(s) <20 mm
The following guidelines prevented considering a patient with good responding lesions ≥20 mm as progressive based on progression of some small lesions (<20 mm) or considering one large stable lesion (≥20 mm) as SD while all the other target lesions (<20 mm) showed progression.
The response was evaluated by taking the sum of the LD for all target lesions (< and ≥20 mm) according to the RECIST criteria.
The definitions of CR, PR and SD remained the same.
PD was defined as either an increase of at least 20% in the sum of LDs of the target lesions or if at least half of the target lesions showed at least doubling of diameters or the appearance of one or more new lesions.
2.2
Stable disease and slow progressive disease SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the sum of LD of target lesions recorded previously but not necessarily at baseline. The minimal time interval required between two measurements for determination of SD was at least 16 weeks.
Slow PD (SPD) was not an endpoint of the study but corresponded to specific protocol conventions that allowed continuing investigational treatment even in case of PD. This progression, in some specific conditions defined below as a SPD status, was not considered as withdrawal criteria. SPD was defined as follows: Eastern Cooperative Oncology Group performance status of 0 or 1, and lactic acid dehydrogenase value >2x the normal upper limit, and no appearance of visceral metastases other than in the lung, and not meeting any criteria for permanent stopping of study treatment.
Safety assessment
All local (injection site) reactions were considered causally related to MAGE-A3 immunotherapeutic administration. Causality of all other adverse events (AEs) was assessed by the investigator.
Serious AEs (SAEs) that were not recovered/resolved were followed-up at subsequent visits/contacts until they had resolved, subsided, stabilized, disappeared or were otherwise explained.
New onsets of autoimmune diseases or other immune-mediated inflammatory disorders were reported from the time of the first treatment administration until last follow-up visit as AEs or SAEs. Grade 3 or higher autoimmune diseases were considered as medically significant and were reported as SAEs.
Abnormal laboratory findings (e.g. clinical chemistry, hematology, urine analysis) or other abnormal assessments that were judged by the investigator to be clinically significant were recorded as AEs or SAEs.
Autoimmune diseases
The following autoimmune diseases and other immune-mediated inflammatory disorders were recorded:
-neuroinflammatory diseases (e.g. optic neuritis, multiple sclerosis, demyelinating disease, transverse myelitis, encephalitis, Guillain-Barré syndrome, myasthenia gravis);
-musculoskeletal disorders (e.g. systemic lupus erythematosus, Sjogren's syndrome, scleroderma, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory rheumatic arthitis, spondylarthropathies such as reactive arthritis and anlylosing spondylitis); 
Details of statistical analyses
Success criteria based on clinical activity were not pre-specified for this study. The probability of observing a certain number of patients (two, three or four of 20) with a clinical response for a range of true response rates was assessed. For example, if the true response rate was 20%, there was more than 80% probability of observing at least three of 20 patients with a clinical response (power). If the true response rate was less than 5%, the probability of observing at least three of 20 patients with a clinical response (alpha risk) was >10%.
Primary immunogenicity analyses were performed on the according-to-protocol population.
Geometric mean concentration (GMC) was calculated by taking the antilogarithm of the mean of the log10 concentrations. Antibody concentrations below the assay cut-off were given an arbitrary value of half the cut-off for the purpose of GMC calculation. MAGE-A3-specific
GMCs were tabulated with 95% confidence interval.
Seropositivity was defined as an antibody concentration greater than or equal to clinical cut-off value. Seropositivity rate was defined as the proportion of patients who were seropositive.
Seroconversion was defined as an antibody concentration greater than or equal to the clinical cutoff value for initially seronegative patient or an antibody concentration greater than or equal to twice the baseline value for patients whose pre-treatment antibody concentration was above the clinical cut-off value.
Geometric mean ratio (GMR or immunogenicity score) was calculated using the percentage of T-cells producing a defined cytokine profile in 24-paired stimulated experimental and reference control condition wells. Only pairs of wells fulfilling pre-defined criteria of minimal amount of CD4+ or CD8+ T-cells and limiting thresholds of unspecific signals in the control condition wells (valid wells) were taken into consideration for the GMR calculation.
Cell-mediated immune (CMI) response was defined as a GMR above the assay cut-off value and at least a four-fold increase of MAGE-A3-specific CD4+ or CD8+ T-cells producing cytokines TNF-α or/and IFN-γ after immunization as compared to the patient's pre-treatment value.
The CD4+/CD8+ T-cell frequencies relative to the cut-off values frequencies were calculated as number of positive wells divided by number of valid wells multiplied by the percentage of CD4+/CD8+ T-cells engaged in the experiment.
BRAF mutational status
Of the nine MAGE-A3-positive patients with available results for BRAF mutational status, three patients had a V600E BRAF mutation. Of the five MAGE-A3-negative patients with available results, two patients had a V600E BRAF mutation, and one patient had a V600K BRAF mutation.
CMI response
The proportion of patients with MAGE-A3-specific single-positive CD4+ T-cells expressing 
Laboratory assessments
Urine sampling for:
Urine pregnancy test
Blood sampling for: Footnote: ATP, according-to-protocol; GS++, patients presenting the gene signature on both biopsies; GS+/-, patients presenting the gene signature on one biopsy and not on the other one; GS-, patients without the gene signature; GM, geometric mean of MAGE-A3-specific immunogenicity score calculated on all patients; PRE, baseline; W, week; 95% CI, 95% confidence interval
